In development: Guidance, quality standards and advice
Showing 1 to 1 of 1
| Title | Type | Expected publication date |
|---|---|---|
| Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer [TSID12065] | Technology appraisal guidance | TBC |